Development of ink-printed RPL technology by Marie Skłodowska-Curie Career FIT Fellow at the University of Limerick

Limerick, Ireland – February 2020. As Industry mentor, GlycoSeLect’s CEO, Robert Dunne, attended the annual review meeting of the Career-FIT project JETLECT – Ink-Jet Printed Recombinant Prokaryotic Lectins for POC Biomedical Diagnostics and High Throughput Biomedical Screening – at the University of Limerick.

Mr Dunne mentors Dr Semen Vasilev, a Marie Skłodowska-Curie fellow, whose research project aims to use GlycoSeLect’s Recombinant Prokaryotic Lectins (RPLs) as diagnostic sensors for disease detection and high throughput screening of biopharmaceuticals.

For this purpose, Dr Vasilev will develop methodologies for ink-jet printing RPLs in a high-density format, generating bio-sensing platforms and, ultimately, building RPL-based arrays for biopharmaceutical screening applications.

“I was delighted to see the progress in the project made by the Dr Semen Vasilev with his academic mentor Dr Emmet O’Reilly. I am looking forward to the publication of 3 research papers and the use of our RPL lectins following the proof of concept work to date”, said GlycoSeLect’s CEO, Robert Dunne.


Career-FIT has received funding from the European Union’s Horizon2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 713654.

About GlycoSelect Ltd

GlycoSeLect Ltd is an early-stage biotechnology company developing proprietary innovative and cost-efficient solutions for the analysis, characterisation and purification of pharmaceutical products. Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of RPLs; proteins that enable the more efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect established a UK based subsidiary in 2015 to support further development, provide wider geographic reach and drive commercialisation.

More Stories